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To validate the use of multicellular spheroids to predict the
efficacy of herpes simplex thymidine kinase/ganciclovir
(HSVtk/GCV) suicide gene therapy in the respective in vivo
tumors, we established and characterized 15 melanoma-
derived cell lines from surgically excised melanoma tumors.
Three HSVtk-lipofected cell lines were not sensitive to GCV
in any culture configuration, other five displayed similar
sensitivity as monolayers or spheroids, and only one resulted
more sensitive when grown as spheroids. Other six cell lines
manifested a relative multicellular resistance (MCR) pheno-
type growing as spheroids, compared with the same cells
growing as monolayers. The reverse correlation between the
MCR and the monolayers survival to HSVtk/GCV suggests
that one of the main causes of MCR would be the rapid cell
repopulation after suicide gene treatment. The high correla-
tion of MCR with the spheroids radial growth and with the
mitotic index of the respective originary tumors supported
this re-growth involvement. A remarkable finding was the
high correlation in HSVtk/GCV sensitivity between in vivo
tumor and the corresponding derived cell lines growing as
spheroids (R2¼ 0.85). This strongly encourages the imple-
mentation of spheroids as highly realistic experimental model
for optimizing and predicting the in vivo response of the
respective tumors to therapeutic strategies.
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Introduction
Canine malignant melanoma is a spontaneous tumor
displaying histopathological features and biological
behavior similar to human melanoma, but a faster
progression and an extremely poor prognosis. This
highly aggressive canine tumor is too invasive to be
cured only by surgical resection and is frequently
resistant to current therapies.1,2 This has prompted
investigations to define new treatment strategies. Intra-
tumor suicide non-viral gene therapy with thymidine
kinase from the herpes simplex virus (HSVtk), in
combination with the pro-drug ganciclovir (GCV), is
one of the emerging strategies against this malignant
disease.3–5 The successful eradication of tumors dep-
ended on the bystander effect,6 by which unmodified
adjacent tumor cells were also destroyed by HSVtk/GCV
cytotoxic effect, allowing an effective tumor regression
produced by only a minority of genetically modified
tumor cells.
Malignant melanoma in dogs is also refractory to
chemotherapy that may be related to drug resistance
manifestation.1,2 Although this property of tumors was
focused for over 20 years on multidrug resistance (MDR),
other kind of resistance called multicellular resistance
(MCR) produced by a solid tissue environment is the
major obstacle to many cancer therapies.7,8 This intrinsic
in vivo resistance might not be observed when cells are
cultured as monolayers. MCR mechanism is only
encountered when cells are cultured as multicellular
spheroids (Sphs). These three-dimensional assemblies
have been used as experimental models to better reflect
the cellular environment that is found in vivo.5–10 Being
highly complex systems, their cellular properties are
dependent on the origin of the tumor cells, their
transformation state, medium and growth conditions.
They offer a versatile in vitro system of intermediate
complexity between monolayer cultures in vitro and
tumors in vivo.5–10 Sphs combine the relevance of
organized tissues with the controlled environment of in
vitro methodology.5–10 These cell aggregates organized in
vitro have a great potential for a number of clinical and
biomedical applications. In brief, they represent a more
realistic experimental model for optimizing and predict-
ing the efficacy of cancer therapies in the respective
in vivo tumors.5–10
Most of the cancer gene therapy studies carried out
on animal models use established tumor cell lines
that were kept in culture for many generations, making
them very different from the original tumors. We here
isolated and characterized 15 canine melanoma cell lines
derived from surgically excised melanoma tumors, in
order to evaluate potential in vivo responses of indi-
vidual spontaneous canine melanomas to suicide gene
therapy.
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Our results strongly suggest that, the in vitro response
of tumor-derived Sphs correlated with the clinical
outcome of the suicide gene treatment observed on
canine melanoma patients in vivo. In addition, we
present evidence showing that the fast cell repopulation
(re-growth) of multicellular Sphs after suicide gene
treatment would be mainly responsible for the canine
melanoma MCR effect.
Results and discussion
Melanoma derived cell lines displayed considerable
heterogeneity
A total of 15 melanoma cell lines, derived from surgically
excised hepatic (Ll) and scapular (Bts) metastasis or from
oral (Br, Bk, Btl Cl, Ds, Fk, Kg, Rka, Rkb, Rd, Sc and Tr)
and ocular (Ak) primary tumors were maintained in
culture for over 100 passages.
In accordance with the measured duplication times
(DT) of cell lines ranging 20–60 passages, we found three
different groups of melanoma cells. A fast group (Bk,
Cl, Ds, Fk, Ll, Sc and Tr) displaying a DTD23 h, an
intermediate group (Br and Rka) displaying a DTD29 h
and a slow group (Ak, Btl, Bts, Kg, Rd and Rkb)
displaying DTD40 h (Table 1). Using flow cytometry
analysis of DNA content, DTs were confirmed as
inversely proportional to the number of cells in S- and
G2/M-phases. Two examples are depicted in Figure 1:
the highly growing Ds cells, increased the fraction of
S-phase cells actively synthesizing DNA and, then, the
relative amount of cells in G2/M phase compared with
the slow-growing Ak cells.
Cultured as monolayers, 13 cell lines displayed
spindle-shaped fibroblastic and 2 epithelioid cell type.
Eight of them were faintly adhesive to plastic, as
reported for other canine melanoma-derived cell lines,16
and the remaining ones displayed normal adherence. Kg
appeared as three different cell types: (i) fibroblast-like,
(ii) large cells with clearly distinguishable nuclei and (iii)
giant multinucleated cells (data not shown). The hetero-
geneity of Kg was indicated by flow cytometry as three
peaks (Figure 1). This was probably due to the hetero-
geneity of the cell cultures as no selection was made to
the primary cultures.
Cultured tumor cells expressed melanoma-specific
markers
Melanocytes arise from the embryonic neuroectoderm
and retain the ability to differentiate into spindled or
epithelioid cells, with the identification of canine
melanoma being difficult in poorly differentiated amela-
notic tumors. Specific markers can help in the diagnosis.
Table 1 Tumor markers in cultured canine melanoma monolayers
No. Cell line Duplication time (h) Vimentin S100 Melan A gp100 Cytokeratin
1 Ak 40.4±0.9 + ++ +++ + 
2 Bk 22.0±2.0 +++ + + + ++
3 Br 29.6±0,2 + +++ +++ ++++ ++++
4 Btl 45.0±4.1 ++++ +++ +++ ++ 
5 Bts 35.1±3.0 ++++ + ++  
6 Cl 20.8±0.2 + + + + 
7 Ds 22.2±1.9 + + +++ + 
8 Fk 22.3±2.4 + +   
9 Kg 41.3±2.3 + ++++ ++ + 
10 Ll 21.5±1.7 + ++   
11 Rd 43.0±1.1 ++++ ++ ++++ ++ +++
12 Rka 28.0±2.0 ++++ + + + ++
13 Rkb 36.7±0.6 + + ++ ND 
14 Sc 25.7±0.3 + ++ ++ + 
15 Tr 22.0±1.0 ++++ + +  +
Abbreviation: ND, not determined.
Cells growing for 3 days in monolayers were fixed and treated for markers staining as described in Materials and methods. Time course of
growth was determined by trypan blue exclusion cell counting. + symbols indicate semi-quantitative visual estimations: + indicates faint,
++ weak, +++ medium and ++++ strong staining.
Figure 1 Flow cytometry analysis: cells growing in monolayers for 2 days were suspended, treated and subjected to analysis as described
in Materials and methods.
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Immunocytochemistry of cells growing as mono-
layers evidenced uniformly low staining of vimentin
(an intermediate filament that is expressed by mesench-
ymal and neuroectodermal cells in normal tissues) in 9 of
15 cell lines. Conversely Bk, Btl, Bts, Rd, Rka and Tr
showed a high vimentin expression. S100, an isoform of a
calcium-binding protein restricted to neuroectodermal
cells, was high in Br, Btl and Kg; moderate in Ak, Ll, Rd
and Sc; and low in Bk, Bts, Cl, Ds, Fk, Rka, Rkb and Tr.
Melan A (expressed in pigmented cells) and gp100
(expressed in activated melanocytes) are two specific and
sensitive melanoma antigens. Melan A was high in Ak,
Br, Btl, Ds and Rd; moderate in Bts, Kg, Rkb and Sc; low
in Bk, Cl, Rka and Tr; and negative in amelanotic Fk and
Ll. In addition, gp100 staining was high in Br; moderate
in Btl and Rd; low in Ak, Bk, Cl, Ds, Kg, Rka and Sc; and
negative in Bts, Fk, Ll and Tr. Although a negative
staining for cytokeratin (a keratinocyte-specific marker)
is expected, five cell lines (Bk, Br, Rd, Rka and Tr)
resulted positive. It is noteworthy that these five
cytokeratin-positive cell lines also co-expressed vimen-
tin, confirming their invasive and metastatic behavior.17
Thus, morphological analysis and the positive staining
for most of the assayed markers (Table 1) confirmed the
diagnosis of melanoma.18
Melanoma cells grew in vitro as multicellular Sphs
All canine melanoma cell lines were able to grow as
multicellular Sphs either in suspension (Figure 2) or as
colonies in soft agar (data not shown). Although Br, Btl,
Bts, Cl, Ds, Fk, Ll and Rd Sph cells appeared intimately
associated with each other and closely packed, Kg, Sc
and Tr formed intermediate cell clusters and Ak, Bk, Rka
and Rkb appeared as loosely associated aggregates of
cells in which single cells could be clearly distinguished
(Figure 2, Table 3).
Melanoma Sphs showed considerable response
diversity to suicide gene therapy
Multicellular Sphs represent a highly valuable in vitro
tumor model to explore how the spatial configuration of
cells could affect the efficacy of the HSVtk/GCV suicide
gene therapy under conditions that more closely resem-
ble the in vivo situation.5,10,19 The cytotoxicity of increas-
ing concentrations (0.01–1000 mg ml1) of the pro-drug
GCV was tested on monolayers and Sphs of transiently
bgal- or HSVtk-expressing melanoma cells.
As shown in Figure 3, sparse growing monolayers
derived from different tumors showed very different
sensitivities to the HSVtk/GCV system. Ak, Bk, Kg, Rka,
Rkb and Sc monolayers were the most sensitive with
lipofection efficiencies varying from 26–53% (Ak, Bk, Rka
and Sc) to 9–12% (Kg and Rkb). On the other hand Br, Fk,
and Ll monolayers presenting intermediate lipofection
efficiencies (10–17%) and Rd in the low efficiency range
(2%) were not sensitive to HSVtk/GCV. Conversely, other
group with low/intermediate lipofection efficiencies
(Btl, Bts, Cl, Ds and Tr: 5–20%) showed intermediate
responses to the assayed system. On the other hand,
bgal-expressing Ds monolayer cultures showed a higher
basal sensitivity to GCV, probably due to high levels of
cellular thymidine kinase activity. This precluded evi-
dencing the additional activity of the transferred HSVtk
gene. Thus, dose–response curves to GCV in bgal- and
HSVtk-lipofected Ds cells were close.
Although HSVtk did not significantly sensitize Br, Fk and
Ll cells to GCV in any culture configuration, Ak, Bts, Ds, Rka
and Tr resulted similarly sensitive as Sphs or monolayers.
On the other hand, HSVtk-lipofected Bk, Btl, Cl, Kg,
Rkb and Sc showed Sph cell survival curves that shifted
rightward compared with the same cells grown as sparse
monolayer, indicating a GCV MCR phenotype when
grown as Sphs.
Surprisingly the Sph survival curves of Rd and Tr
shifted leftward at the pharmacologically relevant doses
of GCV (1–10 mg ml1) and showed, respectively, mod-
erate and relatively high sensitivity, probably due to a
stronger bystander effect in three-dimensional config-
uration that counteracted the MCR effect.
High lipofection efficiency could explain the efficacy
of the HSVtk/GCV suicide system in Ak Sphs (53%), in
which cell-survival curves were similar to those of the
respective sparse monolayers. However, Tr, with inter-
mediate lipofection efficiency (18%), also showed similar
monolayer or Sphs cell-survival curves.
Variability in lipofection efficiencies of cell lines could
explain the heterogeneity of the responses. Nevertheless,
no correlation was observed between monolayers and
Sphs survival of the sensitive group and their lipofection
efficiencies (data not shown).
As shown in Table 2, Sphs/monolayers IC50s evi-
denced that Sphs sensitivity to suicide gene treatment
was quantitatively different for each individual tumor
and independent of the respective monolayers response.
HSVtk-expressing Bk, Btl, Cl, Kg, Rkb and Sc Sphs
resulted hardly sensitive, whereas Bts, Ds and Rka only
moderately sensitive to GCV compared with their
respective monolayers. In assays carried out in three-
dimensional cultures, HSVtk-lipofected Ak, Ds, Rd, Rka,
Rkb, Sc and Tr cells were 3- to 1064-fold more sensitive to
GCV than the corresponding bgal-lipofected controls,
supporting the feasibility of this suicide approach in vivo.
Conversely, HSVtk-lipofected Fk, Kg and Ll Sphs did not
show any significant increased sensitivity to GCV with
respect to the corresponding bgal-lipofected cells. Bk, Br,
Btl, Bts and Cl showed survival values higher than 100%
at the lower concentrations of GCV. Although the HSVtk
survival curves were always below the bgal ones, their
high survival values (450%) precluded the determina-
tion of IC50s for both.
Suicide gene cytotoxicity at an in vivo significant
intratumor GCV concentration
We estimated the HSVtk suicide gene cytotoxicity at
the pharmacologically relevant GCV concentration of
1 mg ml1, similar to an intratumor standard dose of our
canine patients.3,4 Under this condition, that more closely
resemble the in vivo situation, the suicide gene killed a
substantial amount of sensitive HSVtk-expressing cells,
with little effect on bgal-expressing cells (Figure 3).
When grown as sparse monolayers, 4 of 15 cell lines
appeared not to be sensitive to the HSVtk/GCV
(1 mg ml1) system (Figure 4a), whereas the remaining
11 cell lines showed survival values significantly lower
than b-gal lipofected controls (Figure 4b, c). Three of four
cell lines whose monolayers were not affected by the
suicide system maintained the non-responsiveness when
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grown as Sphs. Only Rd Sphs, whose monolayers were
nonsensitive to HSVtk/GCV, were significantly inhibited
by this suicide system (Po0.001). In the susceptible
monolayers (Mnl) group (11 cell lines), 7 cell lines (Ak,
Bk, Bts, Ds, Rka, Rkb and Tr) maintained a significant
response to HSVtk/GCV when grown as Sphs, whereas
the remaining 4, lost their responses (Btl, Cl, Kg and Sc).
Only 6 of 11 cell lines (Bk, Btl, Cl, Kg, Rkb and Sc)
presented MCR phenotype: (%Mnl survival values
significantly lower than %Sph), whereas the remain-
ing 5 (Ak, Bts, Ds, Rka and Tr) did not. Nevertheless,
two of six MCR-positive and five of five MCR-negative
Sphs showed a survival rate significantly lower than
the bgal-expressing Sphs. These results suggest that,
despite the MCR effect, the HSVtk/GCV system is
sufficiently effective to be successfully applied to
melanoma cells both in vitro and in vivo in about 50%
of the cases.
Figure 2 Canine melanoma spheroids morphology: canine melanoma-derived cells growing in suspension for 3 days were observed by
a inverted phase contrast microscope and photographed ( 200).
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In vitro suicide gene resistance of Sphs inversely
correlated with the monolayers’ sensitivity
To quantify the effect of the spatial configuration on the
action of the suicide system we calculated a MCR index
(MCRi) as follows: MCRi¼ (%Sph—%Mnl)/%Mnl. As
shown in Figure 5, we found a reverse correlation
between the MCRi and the percentage of survival
of the monolayers, apparently following a potential
tendency (R2¼ 0.81).
Suicide gene sensitivity of Sphs correlated with the
in vivo tumor response of canine melanoma patients
As it was already reported,3,4 spontaneous melanoma
canine patients received 5-weekly intratumor injections
Figure 3 In vitro HSVtk/GCV effects on monolayers and spheroids: In vitro GCV dose–response curves of canine melanoma-derived bgal
(J, n)- and HSVtk- (m,K)-expressing cells growing as monolayers (n, m) or spheroids (J,K). The assay was performed as described in
Materials and Methods. Results were expressed as mean±s.e.m. of four independent experiments.
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of HSVtk-carrying lipoplexes and GCV. Table 3 sum-
marizes the suicide gene therapy responses of in vivo
tumors and the respective derived cell lines growing as
monolayers and Sphs.
Among the six tumors (Btl, Bts, Br, Cl, Ds and Sc) that
showed stable disease (s.d.) during the 5 weeks of
suicide gene treatment (Table 3), five (except Bts)
maintained their non-response to HSVtk/GCV when
grown as Sphs, whereas five of six (except Br) were
sensitive to suicide gene lipofection when grown as
monolayers (Figure 4). Among the seven tumors that
showed objective responses (Ak, Bk, Kg, Rd, Rka, Rkb
and Tr), six maintained their significant response to
HSVtk/GCV when grown as Sphs, whereas Kg lost it.
Although grown as monolayers, six of seven cell lines
(except Rd) remained sensitive to HSVtk/GCV (Table 3).
A remarkable finding was the high correlation in
HSVtk/GCV sensitivity between in vivo tumors and
the corresponding derived cell lines when grown as Sphs
(R2¼ 0.85). This result became more significant as no
correlation was found with the same transiently lipo-
fected cells cultured as sparse monolayers (R2¼ 0.29)
(Figure 6).
This correlation between the in vitro behavior of Sphs
and the clinical outcome of the HSVtk/GCV treatment on
canine melanoma patients in vivo (Figure 6) strongly
encourages the implementation of Sphs as a highly
realistic experimental model for optimizing and predict-
ing the in vivo response of the respective tumors to
therapeutic strategies.
In addition, these data suggest that the MCR to suicide
gene treatment found in Sphs also occurred in the
tumors in vivo.
One limitation of cultured Sphs in terms of emulating
the tumor microenvironment is the fact that they do not
contain stromal cells, such as fibroblasts, endothelial cells
and immune cells including macrophages, NK, T/B
lymphocytes, etc. Although we can assume that stromal
cells would have a key role in vivo for the long-term
Table 2 In vitro sensitivity to GCV of HSVtk- and bgal-expressing multicellular spheroids and monolayer cultures
Cell line Monolayers Spheroids bgal/HSVtk HSVtk: Spheroid/ Monolayer Lipofection efficiency (%)
bgal HSVtk bgal HSVtk Monolayer Spheroid
Ak 230±78 0.27±0.19 34±17 0.82±0.22 849 41 3 53±14
Bk 12±7 0.025±0.01 41000 41000 474 41 440500 43±8
Br 41000 297±144 41000 41000 3.4 41 43.4 10±1
Bts 760±163 105±74 41000 41000 7.3 41 49,6 11±3
Btl 750±166 6.8±1.5 41000 41000 110 41 4146 5±2
Cl 79±50 5.0±2.0 41000 41000 15 41 186 20±4
Ds 30±10 3.0±2.0 390±132 77±15 10 5 25 9±5
Fk 68±23 39±3.0 56±19 67±21 1.7 0.8 2 10±3
Kg 309±131 0.64±0.45 41000 41000 483 41 41500 9±4
Ll 470±58 477±62 64±26 159±114 1 0.4 0.3 17±8
Rd 336±212 202±117 730±76 30±5 1.7 24 0.15 2±1
Rka 24±16 0.05±0.02 41000 0.94±0.04 474 41064 19 32±9
Rkb 76±32 0.045±0.01 578±153 205±81 1690 2.8 4550 12±1
Sc 392±123 0.14±0.05 41000 133±68 2798 48 946 26±11
Tr 354±110 2.6±1.2 108±32 0.17±0.09 135 650 0,06 18±3
Abbreviations: GCV, ganciclovir; HSVtk, herpes simplex thymidine kinase.
Lipofection efficiency was measured as blue X-Gal-stained cells. The results represent means s.e.m. of (4) independent experiments of GCV
concentrations leading to 50% reduction in cell viability (IC50) from the experiments showed in Figure 3.
Figure 4 In vitro sensitivity to 1 mg ml1 GCV of HSVtk- and bgal-
expressing multicellular spheroids or monolayer cultures. The
results represent means±s.e.m. of four independent experiments
at 1 mg ml1 GCV concentration derived from Figure 3. In this case,
each value was relative to the respective condition in the absence of
GCV. (a) Cells not displaying MCR; (b) cells displaying MCR; and
(c) monolayers not sensitive to the HSVtk/GCV system. HSVtk vs
bgal: ***Po0.001; **Po0.01; *Po0.05. Spheroids vs monolayers:
oooPo0.001; oPo0.05.
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outcome of a treatment, in this particular case, it seems
that the HSVtk/GCV treatment on Sphs, mainly com-
posed by polyclonal tumor cells, constituted a very good
model mimicking the in vivo situation. This suicide gene
system could rely mainly on the direct effect on the
tumor cells. Chopped tumor slices, a model of a limited
amount of tumor containing the whole stromal structure,
showed similar HSVtk/GCV response to those obtained
with the respective Sphs (data not shown). In addition,
canine melanomas usually presented low infiltration of
immune cells, and the increase of this infiltration after
treatment with suicide gene with respect to pretreatment
biopsies was not sufficient to break the immune tolerance
to self-antigens and the immunosuppressive tumor
microenvironment.3 Therefore, the effectiveness of
HSVtk/GCV bystander effect may not be restricted to
the immune cell infiltration response, but specially to
mitochondria amplification of HSVtk/GCV-induced
apoptosis/necrosis. Mitochondrial free radicals, dif-
fusing or passing to adjacent cells leading them to
oxidative damage, would allow that only few HSVtk-
expressing cells could initiate the destruction of almost
the whole Sph.10
In vivo and in vitro tumor cell suicide gene resistance
could be due to ‘re-growth resistance’
The replication active part of Sphs, sensitive to the
suicide system, mainly belongs to the outer layers of
Sphs, as monolayers on the surface of a sphere.10,15 Then,
it could be inferred that the inverse correlation between
Sphs MCR and monolayers survival would be due to a
faster repopulation, through recruitment of the surviving
quiescent cells to the proliferative fraction after suicide
gene treatment.10,15,20 If this were the case, the MCRi
should correlate with the rate of Sph radial growth. This
was, in fact, observed (as shown in Figure 7a), because
the daily radial increase of Sphs during the linear phase
of growth was proportional to that of the MCRi,
following a linear tendency (R2¼ 0.98). Conversely, no
correlation was found between the monolayers DT and
the MCRi (R2¼ 0.126) or the daily Sphs radial increase
(R2¼ 0.303) (plots not shown). Furthermore, we did not
find any correlation between MCRi and the degree of
compactness of Sphs, parameter that can modify non-
viral transgene expression.15
The phenomenon, termed ‘re-growth resistance,’ has
already been showed in patients and it was found also in
Sphs.20–21 After radiotherapy or chemotherapy, a great
proportion of well-oxygenated external cycling cells die.
Subsequently, quiescent cells that become situated at the
periphery of the Sphs have better access to nutrients.
These quiescent cells thus return to the cell cycle, resume
growth and the new cells take the vacant places in the
tumor.
Figure 5 Spheroid multicellular resistance index (MCRi): Correla-
tion at 1 mg ml1 GCV with respect to the survival of the
corresponding the monolayer. Each dot corresponds to an indivi-
dual experiment. Only cell lines displaying MCR were included in
the plot. Tendency curves were calculated by potential regression.
Table 3 Melanoma responses to suicide gene transfer
Patient/cell line In vivo In vitro
Tumor mitotic index Tumor volumes Clinical Response Survival (%) Spheroids Compactness
Initial (cm3) Final (%) Monolayers Spheroids
Ak 2.5±0.3 1±0.2 25±3 PR 31±5 46±3 +
Bk 3.3±0.7 15±2 49±5 PR 22±3 64±5 +
Br 4.2±0.5 4±0.4 70±8 s.d. 87±7 79±3 +++
Btl 4.0±0.6 25±3 123±14 s.d. 65±3 97±8 +++
Bts 2.5±0.3 87±9 59±7 s.d. 72±5 72±10 +++
Cl 2.0±0.4 36±5 85±9 s.d. 66±6 87±8 +++
Ds 4.1±0.5 17±2,3 65±8 s.d. 73±12 81±8 +++
Fk 4.5±0.7 12±2 4600 PD 98±5 107±5 +++
Kg 3.5±0.4 3±1 50±7 PR 41±8 78±13 ++
Ll 4.5±0.6 13±1.4 4345 n.t. PD 103±4 116±6 +++
Rd 3.9±0.5 25±3.5 48±6 PR 78±5 62±6 +++
Rka 3.2±0.4 20±2.4 43±5 PR 30±4 51±2 +
Rkb 3.0±0.3 55±7.8 48±7 PR 42±5 67±7 +
Sc 4.0±0.4 12±1.5 62±8 s.d. 34±7 84±3 ++
Tr 2.2±0.2 22±3.2 35±5 PR 55±6 38±5 ++
Abbreviations: n.t., not treated; PD, progressive disease; PR, partial response; s.d., stable disease.
Canine patients were treated and tumor volumes were measured at day 42 as described.4 Monolayers and spheroids survivals correspond
to 1 mg ml1 GCV pro-drug concentration (see Figure 3).
Tumor mitotic index was the average number of mitotic figures counted in 10 consecutive, non-overlapping high-power fields (500 mm
in diameter). + symbols are used for the degree of compactness as seen in Figure 2.
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As expected, MCRi also correlated with the mitotic
index of the original tumors (R2¼ 0.93), strongly sup-
porting the theory of fast repopulation by cell re-growth
as responsible of the MCR (Figure 7b). These results, in
agreement with already reported data showing that the
mitotic index highly correlated with malignancy,22 would
explain the extremely fast in situ progression of these
highly aggressive tumors in the patients.4
As derived from Figure 7a and b, the correlation
between the mitotic indexes of the original tumors and
radial growth rate of the derived Sphs (R2¼ 0.95, plot not
shown) confirmed the behavioral similarity between in
vivo tumors and their in vitro models.
During our veterinary clinical study, Kg patient
displayed a partial response, whereas Btl, Cl and Sc
patients presented stable disease during the 5-weekly
suicide gene treatments.4 The Sc tumor had shown rapid
progression in situ before gene therapy, with the volume
increasing about five-fold in only 5 weeks (12.0–63.7 ml).
Through the 5-weekly suicide gene treatment, tumor
growth ceased and subsequently displayed a 38% size
reduction. There was little change in size for the
following 10 weeks and after that growth resumed.4
On the other hand, the suicide gene resistance
observed in Ll and Fk tumors and derived cultures,
strongly suggested re-growth resistance, even in the fast-
growing monolayers. This was supported by their high
mitotic index (4.5) (Table 3) and by the extremely rapid
growth shown by these highly malignant amelanotic
tumors in vivo.4 Fk tumor had shown rapid increase in
size (about 13-fold: 12.0–158.7 ml), in only 5 weeks of
gene therapy, while a de-pigmenting process started.
Rapid progression was also shown in Ll untreated, not
easily reachable liver metastasis.4
Re-growth resistance to HSVtk/GCV treatment
was confirmed by flow cytometry analysis
To get a deeper insight into the cellular response to
HSVtk/GCV treatment, we checked its effects on the cell
Figure 6 In vitro vs in vivo sensitivity to the suicide gene system:
Correlation of the in vitro cell survival with suicide gene/GCV
(1 mg ml1) in monolayers (m) and spheroids (K) at day 5 and
12, respectively (Figure 4), and the in vivo original tumor res-
ponses after 5-weekly treatments (Table 3). Only PR and s.d.
responses were considered (Table 3). Tendency curves were
calculated by polynomial regression. Monolayers: lower curve.
Spheroids: upper curve.
Figure 7 Correlation between the MCRi and (a) the radial growth rate of the tumor-derived spheroids and (b) the mitotic indexes of the
original tumors. See Table 3. Tendency curves were calculated by linear (a) and polynomial (b) regression. Spheroids daily radial growths
(mm) were determined as described in Materials and Methods: Bk, 7.0±1.0; Btl, 3.0±0.2; Cl, 3.3±0.1; Kg, 6.5±0.7; Rkb, 4.5±0.4; and Sc:
9.0±0.9.
Figure 8 Flow cytometry analysis of in vitro untreated or bgal- and HSVtk-lipofected high-density Sc monolayers: Cells were grown for 48 h
in the absence (control) or the presence (bgal and HSVtk) of 1 mg ml1 GCV, suspended and treated as described in Materials and Methods.
Ap, apoptosis.
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cycle of high-density Sc monolayers by flow cytometry
analysis (Figure 8). The mechanisms involved in cell
killing confined to the outer layers of Sphs (as mono-
layers on the Sph surface) were similar to those of near
confluent monolayers.5,10,15
As expected, bgal-lipofected cells were not sensitive
to 1 mg ml1 GCV, showing the typical cell-cycle peaks
in G0/G1, S and G2/M phases as in non-lipofected
cells. Conversely, HSVtk/GCV-treated cells displayed a
complex pattern where most of the cells accumulated in
S and G2/M phases, whereas about one-third of the total
cells (31.3%) in the hypodiploid sub-G1 apoptotic region
displayed DNA degradation. It is noteworthy that
suicide gene treatment also induced hyperploid progres-
sion, increasing the fraction of cycling, diploid and
hyperdiploid cell populations actively synthesizing
DNA. Then, in HSVtk/GCV-treated group, most of the
cells continue to undergo DNA synthesis in agreement
with the extremely rapid growth shown by these highly
aggressive tumors in the veterinary patient. These data
strongly support re-growth resistance, even in the fast-
growing monolayers.
Conclusion
The development of new therapeutic strategies requires
simple in vitro models that resemble the in vivo situation
in order to select better treatments against solid tumors
and to decrease the use of experimental animals. These
models might serve as a base for a more rigorous
secondary in vitro screening.
These data presented in this study suggest that
monolayers and multicellular Sphs represent two very
different experimental tumor models. Although the
experiments carried out in monolayer cultures could
not predict the effects of the in vivo treatments, the
in vitro sensitivity of Sphs highly correlated with the
clinical outcome of the HSVtk/GCV treatment on
canine melanoma patients in vivo (R2¼ 0.85, Figure 6).
This remarkable finding strongly encourages the im-
plementation of Sphs as highly realistic experimental
model for optimizing and predicting the in vivo response
of the respective tumors to therapeutic strategies.
We found considerable response diversity to suicide
gene therapy: some tumor Sphs responded well (6 of 15
displayed growth inhibition 430%), whereas others
showed no such response (6 of 15 displayed growth
inhibition o20%). In vivo, all the corresponding tumors
presented partial response or stable disease to suicide
gene therapy. Only one patient (Kg) with PR response
in vivo generated poorly responsive Sphs. Thus, in this
sample of 15 tumors, we found 47% (7/15) objective
responses. Previously, we had reported 44% (7/16), 47%
(21/45),3 and 49% (25/51)4 in vivo objective responses to
the suicide gene system.
On the other hand, our observations suggest that
opposing to the suicide gene treatment, there is an
underlying Sphs MCR mechanism whose strength
would be intrinsic of each individual tumor and
independent of the respective monolayers response.
Thus, the causes of relative MCR of tumor Sphs to
therapy would be multiple: (i) the origin and type of
tumor cells, (ii) their proliferation state and (iii) the
heterogeneity of tumor structure.20,21 Sphs, as experi-
mental models to better reflect the in vivo tumor
behavior, showed that one of the main causes of MCR
would be the rapid cell repopulation (re-growth) after
suicide gene treatment. The MCRi of the derived Sphs
not only inversely correlated with the monolayers
suicide gene sensitivity but also directly correlated with
the rate of Sph growth and the mitotic index of the
original tumors (Figures 5 and 7). These facts, and the
highly increased fraction of HSVtk/GCV-treated cells
actively synthesizing DNA accumulated in S and G2/M
phases as evidenced by flow cytometry analysis, strongly
supported the ‘re-growth resistance’ theory.
A highly positive message emerging from these data is
the biological and clinical significance of these observa-
tions: the possible use of a new approach to evaluate the
efficacy of drugs and other cancer therapies in sponta-
neous in vivo tumors. In addition to specific tumor cell
marker evaluation, multicellular Sphs of each patient
tumor represent a useful model (i) to find the best cancer
therapies for each spontaneous in vivo tumor and (ii) to
select patients who might benefit from a specific therapy.
All this provides the rationale for future controlled
therapy trials of multicellular Sphs of each patient
tumor-directed therapy versus physician’s choice to
determine whether assay-directed treatment can im-
prove the patient’s response and survival.
Materials and methods
Cell cultures
Cultured cells derived from surgically excised canine
melanomas were obtained by enzymatic digestion of
tumor fragments with 0.01% Pronase (Sigma, St. Louis,
MO, USA) and 0.035% DNase (Sigma) or by mechanical
disruption in serum-free culture medium.10,11 They were
cultured as monolayers and multicellular Sphs at 37 1C
in a humidified atmosphere of 95% O2/5% CO2 with
Dulbecco’s modified Eagle’s medium/F12 medium (In-
vitrogen, Carlsbad, CA, USA) containing 10% fetal
bovine serum (Invitrogen), 10 mM HEPES (4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid) (pH 7.4) and
antibiotics. Serial passages were done by trypsinization
(0.25% trypsin and 0.02% EDTA in phosphate-buffered
saline) of sub-confluent monolayers.
Immunocytochemistry
Cells attached onto a glass slide were cultured for 48 h in
the above-described conditions. Then, the cells were
washed, fixed with cold acetone, dried, re-hydrated and
incubated separately with the following specific mono-
clonal antibodies as described by the manufacturers:
anti-human melan A (BioGenex, San Ramon CA, USA;
clone A103), anti-human S-100 (BioGenex; clone 15E2E2),
anti-human GP100 (BioGenex; clone HMB45) anti-
human vimentin (Dako, Glostrup, Denmark; clone V9);
anti-human cytokeratin (Dako; clones AE1/AE3). After
washing, cells were incubated with Multi-Link immuno-
globulins (BioGenex) followed by streptavidin/peroxidase
conjugate and developed with 3,30-diaminobenzidine.
Plasmids
Plasmid psCMVb was built by replacing the HSV
thymidine kinase gene of psCMVtk 10 by Escherichia coli
b-galactosidase gene from pCMVb.12 Plasmids were
amplified in E. coli DH5a (Invitrogen), grown in LB
medium containing 100 mg ml1 neomycin and purified
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by ion-exchange chromatography (Qiagen, Valencia,
CA, USA).
Liposome preparation and in vitro lipofection
DC-Chol (3bN-(N0,N0-dimethylaminoethane)-carbamoyl
cholesterol) and DMRIE (1,2-dimyristyloxypropyl-3-
dimethyl-hydroxyethilammonium bromide) were syn-
thesized and kindly provided by BioSidus (Buenos Aires,
Argentina). DOPE (1,2-dioleoyl-sn-glycero-3-phosphati-
dyl ethanolamine) was purchased from Sigma. Lipo-
somes were prepared at lipid/co-lipid molar ratios of 3:2
(DC-Chol/DOPE) or of 1:1 (DMRIE/DOPE) by sonica-
tion as described.13,14 Optimal lipid mixtures were
determined for every cell line.10
Cultured cells at a density of 5 104 cells per cm2
(about 40% confluence) were exposed to lipoplexes
(1 ml liposomes per cm2 and 0.5 mg DNA per cm2) during
4–6 h.10
b-Galactosidase staining
To measure gene transfer efficiency, psCMVb-lipofected
cells were trypsinized, fixed in suspension, stained with
5-bromo-4-chloro-3-indolyl b-D-galactopyranoside (X-
GAL, Sigma) and counted using an inverted phase
contrast microscope.10
Sensitivity to GCV assay
At 24 h after lipofection, both transiently HSVtk- and
bgal-expressing cells, were seeded on regular plates as
monolayers (3.5–7.0 104 cells per ml) or on top of 1.5%
solidified agar to form Sphs (2.0 105 cells per ml) and
incubated with medium containing from 0.01 to
1000 mg ml1 GCV (synthesized and kindly provided by
BioSidus). After 5 days in monolayers or 12 days in Sphs,
cell viability was quantified using a colorimetric CellTiter
96 Aqueous Non-Radioactive MTS Cell Proliferation
Assay according to the manufacturer’s instructions
(Promega, Madison, WI, USA). The percentage of cell
survival was calculated from the ratio of the absorbances
between cells incubated in the presence or absence of
GCV.10 The cell sensitivity to GCV, expressed as the pro-
drug concentration that inhibited cell survival by 50%
(IC50), was estimated from dose–response curves.
Sphs growth
The size of sparse growing MCS was estimated during
a period of 15 days using a Neubauer chamber (Thomas
Scientific, Swedesboro, NJ, USA) under an inverted micro-
scope.10,15 The average diameter of MCS was recorded
as measure of two diameters. Results were expressed
as mean (of a minimum of 15 Sphs diameters)±s.e.m.
(n¼ four independent assays).
Flow cytometry cell-cycle analysis
Untreated cells or both HSVtk- and bgal-expressing cells
in culture in the presence of 1 mg ml1 GCV for 48 h were
trypsinized, fixed in 70% (v/v) ethanol at 20 1C for 1 h,
treated with RNase, stained with 10 mg ml1 propidium
iodide for 30 min and subjected to single-channel flow
cytometry on a Becton Dickinson FACScan (Franklin
Lakes, NJ, USA), with collection and analysis of data
performed using Becton Dickinson CELLQuest soft-
ware.5
Patients
Dogs with a confirmed histopathological diagnostic
of melanoma were recruited for a study as it was
reported.3,4 The dogs’ owners were notified about the
experimental nature of the treatment, and all of them
granted written informed consent for treatment.3,4 The
treatment was performed by specially trained veterinary
professionals, working in accordance with the laws and
regulations of our country (Argentina). All scientific and
ethical issues related to the veterinary clinical trial were
evaluated and approved by the appropriate committee of
the granting agency (ANPCYT, Argentina).
Treatment
The patients selected for this study displayed local
disease (partially removed tumor, or postsurgical re-
lapse) and received multiple injections of lipoplexes
carrying psCMVtk (1–4 mg DNA) co-delivered with
GCV (5–20 mg) in the remaining tumor or adjacent
areas, according to tumor size. At 24 and 48 h after SG
plus GCV delivery, patients orally took 400–800 mg of
acyclovir according to their weight. They continued with
a weekly local treatment chronically or until disappear-
ance of any evidence of local disease.4 In addition,
between 5 and 10 days after surgery, patients were
clinically controlled and treated once a week for 5 weeks
with a subcutaneous vaccine composed of autologous
and/or allogeneic formalized tumor cells and irradiated
living CHO xenogeneic cells producing 20–30 mg of hIL-
2 and hGM-CSF.4 Tumor volumes were calculated as
4/3 p r1 r2 r3.4
Statistics
Results were expressed as mean±s.e.m. (n: number of
experiments corresponding to independent assays).
Differences between groups were determined by analysis
of variance (ANOVA).
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
We thank Graciela Zenobi for technical assistance, Lina
Marino for expert immunocytochemical analysis and
Marı´a D Riveros and Dr Armando L Karara for their
contribution in the early stages of this study. This study
was partially supported by a grant from ANPCYT-
FONCYT: BID1728/OC-AR—PICT 2002—12084 and
PID-UBACYT-2008/2010—M027. G.C.G. and L.M.E.F.
are investigators, and M.L.G.C. and M.S.V. are fellows
of the Consejo Nacional de Investigaciones Cientı´ficas
y Te´cnicas (CONICET, Argentina).
References
1 Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace
LW, Fard A et al. Retrospective study of 338 canine oral
melanomas with clinical, histologic, and immunohistochemical
review of 129 cases. Vet Pathol 2000; 37: 597–608.
2 Smith SH, Goldschmidt MH, McManus PM. A comparative
review of melanocytic neoplasms. Vet Pathol 2002; 39: 651–678.
Suicide gene therapy on canine melanoma
ML Gil-Cardeza et al
35
Gene Therapy
3 Finocchiaro LME, Fiszman GL, Karara AL, Glikin GC. Suicide
gene and cytokines combined non viral gene therapy for canine
spontaneous melanoma. Cancer Gene Ther 2008; 15: 165–172.
4 Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine
and suicide gene therapy as surgery adjuvant treatments
for spontaneous canine melanoma. Gene Therapy 2008; 15:
267–276.
5 Altamirano NA, Karara AL, Villaverde MS, Fiszman GL, Glikin
GC, Finocchiaro LME (2007). Spontaneous canine melanoma
derived spheroids display individual multicellular resistance
patterns to suicide gene and chemotherapy. In: Torres LS
(ed). Cancer Drug Resistance Research Perspectives. Nova Science
Publishers, Inc.: New York., pp 119–137, ISBN: 1-60021-572-6.
6 Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-
thymidine kinase/ganciclovir cancer gene therapy: role of gap-
junctional intercellular communication. Cancer Res 2000; 60:
3989–3999.
7 Desoize B, Jardillier JC. Multicellular resistance: a paradigm for
clinical resistance? Crit Rev Oncol Hematol 2000; 36: 193–207.
8 Santini MT, Rainaldi G. Three-dimensional spheroid model in
tumor biology. Pathobiology 1999; 67: 148–157.
9 Sutherland RM. Cell and environment interactions in tumor
microregions: the multicell spheroid model. Science 1998; 240:
177–184.
10 Finocchiaro LME, Bumaschny VF, Karara AL, Fiszman GL,
Casais CC, Glikin GC. Herpes simplex virus thymidine kinase/
ganciclovir system in multicellular tumor spheroids. Cancer Gene
Ther 2004; 11: 333–345.
11 Karara AL, Bumaschny VF, Fiszman GL, Casais CC, Glikin GC,
Finocchiaro LM. Lipofection of early passages of cell cultures
derived from murine adenocarcinomas: in vitro and ex vivo
testing of the thymidine kinase/ganciclovir system. Cancer Gene
Ther 2002; 8: 96–99.
12 MacGregor GR, Caskey T. Construction of plasmids that express
E coli b-galactosidase in mammalian cells. Nucleic Acids Res 1989;
17: 2365–2365.
13 Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R
et al. Enhanced gene delivery and mechanism studies with a
novel series of cationic lipid formulations. J Biol Chem 1994; 269:
2550–2561.
14 Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene
Therapy 1995; 2: 710–722.
15 Casais CC, Karara AL, Glikin GC, Finocchiaro LME. Effects of
spatial configuration on tumor cells transgene expression. Gene
Ther Mol Biol 2006; 10: 207–222.
16 Inoue K, Ohashi E, Kadosawa T, Hong SH, Matsunaga S,
Mochizuki M et al. Establishment and characterization of four
canine melanoma cell lines. J Vet Med Sci 2004; 66: 1437–1440.
17 Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel
KM et al. Coexpression of vimentin and keratins by human
melanoma tumor cells: correlation with invasive and metastatic
potential. J Natl Cancer Inst 1992; 84: 165–174.
18 Koenig A, Wojcieszyn J, Weeks BR, Modiano JF. Expression of
S100a, vimentin, NSE, and melan A/MART-1 in seven canine
melanoma cells lines and twenty-nine retrospective cases of
canine melanoma. Vet Pathol 2001; 38: 427–435.
19 Mueller-Klieser W. Tumor biology experimental therapeutics.
Critical Rev Oncol Hematol 2000; 36: 123–139.
20 Brown JM, Giaccia AJ. The unique physiology of solid tumors:
opportunities (and problems) for cancer therapy. Cancer Res
1998; 58: 1408–1416.
21 Siemann DW. The tumor microenvironment: a double-edged
sword. Int J Radiat Oncol Biol Phys 1998; 42: 697–699.
22 Spangler WL, Kass PH. The histologic and epidemiologic bases
for prognostic considerations in canine melanocytic neoplasia.
Vet Pathol 2006; 43: 136–149.
Suicide gene therapy on canine melanoma
ML Gil-Cardeza et al
36
Gene Therapy
